Publications

1. Desai B, Wafaa H, Quinn D, Jadvar H: "FDG PET/CT demonstration of pancreatic metastasis of prostate cancer", Clin Nucl Med 36(10):961-2; 2011. [NIH-NCI R01-CA1116101 Support]

2. Desai B, Gross M, Jadvar H: "Multimodality imaging with 18F-NaF PET-CT, 18F-FDG PET-CT, 99mTc-MDP Bone Scintigraphy, and MRI for early detection of skeletal metastasis in a patient with biochemically recurrent prostate cancer", Rev Esp Med Nucl; 2012.

1. Jadvar H, Desai B, Ji L, Conti P, Dorff T, Groshen S, Gross M, Pinski J, Quinn D: "Prospective evaluation of ¹⁸F-NaF and ¹⁸ F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer", Clin Nucl Med 37(7):637-643; 2012. [Abstract] [NIH-NCI R01-CA1116101 Support]

2. Jadvar H, Desai B, Ji L, Groshen S, Conti P, Dorff T, Pinski J, Quinn D: "¹⁸F-flurodeoxyglucose PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer", J Nucl Med; 2013 [NIH-NCI R01-CA111610 Support]

3. Jadvar H, Desai B, Ji L, Groshen S, Conti PS, Dorff T, Pinski J, Quinn D: "Impact of early treatment response assessment on prediction of overall survival in metastatic prostate cancer: RECIST 1.0 vs. PERCIST 1.0", Eur J Nucl Med Mol Imaging; 2014. (In Preparation) [NIH-NCI R01-CA111610 Support]

4. Jadvar H, Desai B, Ji L, Conti P, Dorff T, Groshen S, Gross M, Pinski J, Quinn D: "¹⁸F-fluorodeoxyglucose PET-CT in metastatic prostate cancer: comparison of RECIST 1.0, EORTC, PERCIST 1.0 and PCWG2-PSA treatment response criteria", J Nucl Med; 2014. [NIH-NCI R01-CA111610 Support]

5. Jadvar H, Desai B, Conti PS: "Sodium 18F-Fluoride PET/CT of Bone, Joint and Other Disorders", Semin Nucl Med 2014. (Invited Review Article)(In Review)

6. Chung YY, Desai B, Ji L, Groshen SG, Jadvar H: "Comparative Performance of PET tracers in biochemical recurrence of prostate cancer: A critical analysis of literature", Am J Nucl Med Mol Imaging 2014. (In Review)

7. Mittul Gulati, James Hu, Bhushan Desai, Darryl Hwang, Edward Grant, Vinay Duddalwar: "Contrast Enhanced Ultrasound of Soft Tissue Sarcomas for Monitoring of Neoadjuvant Chemotherapy: A Preliminary Report.", BioMed Research International 2014. (In Review)

8. Jadvar H, Desai B, Piatek C, Ji L, Groshen S, Quinn D: "RECIST 1.0 vs. 1.1: tumor burden and treatment response assessment in metastatic prostate cancer", Urol Oncol; 2014. (In Preparation) [NIH-NCI R01-CA111610 Support]

9. Duddalwar V, Desai B, Desai M, Gill I, Grant E: "Contrast enhanced ultrasound in the evaluation of renal masses in patients with poor renal function", AJR; 2014. (In Preparation)

10. Chen F, Huhdanpaa H, Hwang D, Berhhard JC, Sherrod A, Gill I, Desai M, Desai B, Duddalwar V: "Whole Lesion Quantitative CT Evaluation of Renal Cell Carcinoma: Differentiation of Clear Cell from Papillary Renal Cell Carcinoma", AJR; 2014. (In Preparation)

1. Jadvar H, Desai BB, Conti PS, Dorff T, Groshen S, Pinski J, Quinn D, Ye W: "Detection of lymphadenopathy with FDG PET-CT in men with metastatic prostate cancer", Proc SNM 57th Ann Meeting,Salt Lake City, UT, In: J Nucl Med 51(Supp 2):126P; 2010. [NIH-NCI R01-CA1116101 Support]

2. Jadvar H, Desai B, Conti PS, Groshen S, Pinski J, Quinn D: "Clinical predictors of bone disease on FDG PET/CT in men with metastatic prostate cancer", RSNA 96th Scientific Assembly & Ann Meeting, Chicago, IL, 2010. [NIH-NCI R01-CA1116101 Support]

3. Jadvar H, Desai B, Conti P, Dorff T, Gross M, Quinn D: " Preliminary Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Metastatic Disease in Men with PSA Relapse after Treatment for Localized Primary Prostate Cancer", Proc SNM 58th Ann Meeting, San Antonio, TX; 2011.

4. Jadvar H, Desai B, Quinn D, Dorff T, Pinski J, Conti P; Groshen S: " Treatment Response Assessment of Metastatic Prostate Cancer with FDG PET/CT", Proc SNM 58th Ann Meeting, San Antonio, TX; 2011.

5. Desai B, Piatek C, Tang R, Hu J, Goldkorn A, Gross M, Hawes D, Jadvar H, Dorff T, Quinn D: " Risk stratification and stage migration effect of novel imaging and biomarker technology in men with biochemical failure after local therapy for prostate cancer", Proc Am Soc Clin Oncol Ann Meeting, Chicago, IL; 2011.

6. Piatek C, Desai B, Wei-Tsao D, Tang R, Acosta F, Pinski J, Dorff T, Goldkorn A, Jadvar H, Quinn D: " RECIST 1.0 vs. 1.1: Implications for trial interpretation and design in advanced prostate cancer.",Proc Am Soc Clin Oncol Ann Meeting, Chicago, IL; 2011.

7. Jadvar H, Desai B, Ji L, Quinn D, Dorff T, Gross M, Groshen S: "Association between 18F-NaF and FDG PET/CT and PSA in men with prostate cancer and biochemical relapse", RSNA 97th Scientific Assembly & Ann Meeting, Chicago, IL, 2011. [NIH-NCI R01-CA1116101 Support]

8. Jadvar H, Desai B, Ji L, Quinn D, Dorff T, Pinski J, Conti P, Groshen S: "Comparison of Imaging- and PSA-Based Treatment Response Criteria in Metastatic Prostate Cancer: A Preliminary Analysis", RSNA 97th Scientific Assembly & Ann Meeting, Chicago, IL, 2011. [NIH-NCI R01-CA1116101 Support]

9. Desai B, Piatek C, Ji L, Groshen S, Quinn D, Jadvar H: "RECIST 1.0 vs. 1.1: Tumor Burden and Treatment Response Assessment in Metastatic Prostate Cancer", World Molecular Imaging Congress, San Diego, CA, 2011. [NIH-NCI R01-CA1116101 Support]

10. Jadvar H, Desai B, Ji L, Conti PS, Dorff T, Pinski J, Quinn D, Groshen S: "Prognostic utility of FDG PET/CT in men with castrate-resistant metastatic prostate cancer", Proc SNM 59th Ann Meeting, Miami Beach, FL; 2012. [NIH-NCI R01-CA1116101 Support]

11. Jadvar H, Desai B, Ji L, Conti PS, Dorff T, Pinski J, Quinn D, Groshen S: "Impact of early treatment response assessment on prediction of overall survival in metastatic prostate cancer: RECIST 1.0 vs. PERCIST 1.0",Proc SNM 59th Ann Meeting, Miami Beach, FL; 2012. [NIH-NCI R01-CA1116101 Support] [Top 10 Scientific Poster]

12. Duddalwar V, Desai B, Desai M, Gill I, Grant E: "Contrast enhanced ultrasound in the evaluation of renal masses in patients with poor renal function", 98th Scientific Assembly & Ann Meeting, Chicago, IL, 2012.

13. Jadvar H, Desai B, Ji L, Groshen S, Conti P, Quinn D, Dorff T, Pinski J: "Prediction of time to hormonal treatment failure or death in men with castrate-sensitive metastatic prostate cancer", RSNA 98th Scientific Assembly & Ann Meeting, Chicago, IL, 2012. [NIH-NCI R01-CA1116101 Support]

1. Jadvar H, Desai B: "A pictorial review of FDG PET/CT in prostate cancer", Proc RSNA 96th Scientific Assembly & Ann Meeting, Chicago, IL, 2010.

2. Desai B, Jadvar H: "[F18]-FLUORODEOXYGLUCOSE [FDG] PET/CT in metastatic prostate cancer", WRSNM meeting, Anaheim, CA, 2010.

3. Desai B, Jadvar H: "[F18]-FLUORODEOXYGLUCOSE [FDG] PET/CT in metastatic prostate cancer”, ACNM annual meeting & SNM mid-winter session, Palm springs, CA, 2011.

4. Desai B: "A pictorial review of FDG PET/CT in prostate cancer", 3^rd Annual GPSS Poster Symposium, Los Angeles, CA, 2011.

5. Jadvar H, Desai B: "18F-NaF PET/CT in Biochemical Recurrence of Prostate Cancer", Proc RSNA 97th Scientific Assembly & Ann Meeting, Chicago, IL, 2011.

6. Desai B: "Association between 18F-NaF and FDG PET/CT and PSA in men with prostate cancer and biochemical relapse" 4^th Annual GPSS Poster Symposium, Los Angeles, CA, 2012

7. Desai B, E Allgood, V Pham: "F18 NaF PET/CT in the Assessment of Metabolic Bone Disease and Monitoring of Response to Therapy - Preliminary Results" RSNA 99^th Scientific Assembly & Ann Meeting, Chicago. IL, 2013.

8. Desai B: "Imaging-based Criteria for Assessment of Therapy Response-Current Approaches and Challenges" RSNA 99^th Scientific Assembly & Ann Meeting, Chicago. IL, 2013.

9. A Gera, I Lekht, Desai B, et al: "Applications of Contrast Enhanced Ultrasound for Radiofrequency Ablation of Hepatocellular Carcinoma" RSNA 99^th Scientific Assembly & Ann Meeting, Chicago. IL, 2013.

10. H Malhi, Desai B, E G Grant: "Can Contrast Enhanced Ultrasound Replace Contrast Enhanced CT for Therapy Response Surveillance in TACE Treated Hepatocellular Carcinoma? - Preliminary Results" RSNA 99^th Scientific Assembly & Ann Meeting, Chicago. IL, 2013.

11. M Gulati, Desai B, V A Duddalwar: "Role of Contrast Enhanced Ultrasound for Therapy Response Evaluation in Soft Tissue Sarcomas with Preliminary results" RSNA 99^th Scientific Assembly & Ann Meeting, Chicago. IL, 2013.

12. Desai B, Jadvar H: "The Utility of [F18]-Fluorodeoxyglucose PET/CT for Imaging Prostate Cancer: A Pictorial Guide", RSNA 100^th Scientific Assembly & Ann Meeting, Chicago, IL, 2014.

13. Chalmers B, Desai B, Lee S, Larsen L, et al: "Role of contrast enhanced ultrasound and shear wave elastography for assessment of treatment response to neoadjuvant chemotherapy in breast cancer - Preliminary results" RSNA 100 th Scientific Assembly & Ann Meeting, Chicago. IL, 2014.

14. Hwang D, Nguyen B, Mcbirney S, Desai B, Duddalwar V: Multi Material 3D printing to create anatomic models for patient education and pre-surgical planning. RSNA 100th Scientific Assembly & Ann Meeting, Chicago. IL, 2014.

15. Booker M, O'connell R, Desai B, Duddalwar V: Quality improvement with Discrete Event Simulation (DES): A primer for radiologists. RSNA 100th Scientific Assembly & Ann Meeting, Chicago. IL, 2014.

16. Nayyar M, Desai B, Duddalwar V: Role of imaging in active surveillance of small renal masses - A systematic review of literature. RSNA 100th Scientific Assembly & Ann Meeting, Chicago. IL, 2014.